Browsing Tag
CD388
2 posts
CD388 in focus as Merck announces $9.2bn deal for Cidara Therapeutics (NASDAQ: CDTX)
Merck is acquiring Cidara Therapeutics for $9.2B to expand into long-acting antivirals. Find out what makes CD388 a potential flu game-changer.
Merck announces acquisition of Cidara Therapeutics in bid to strengthen its infectious disease portfolio
Find out how Merck’s acquisition of Cidara Therapeutics could reshape long-acting influenza prevention and expand the company’s infectious disease pipeline.